EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

KTE-X19 autologous anti-CD19 CAR T-cell therapy in patients with R/R B-ALL: Long-term phase I ZUMA-4 results

Despite the availability of novel therapies, clinical outcomes remain poor in the 10‒20% of...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

The UKALL-HeH model could potentially redefine low-risk high hyperdiploidy in pediatric acute lymphoblastic leukemia

Approximately 30% of pediatric patients with acute lymphoblastic leukemia (ALL)...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

When is it safe to schedule an allo-HSCT after COVID-19 infection?

During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

A review of antibody and cellular immunotherapies for adults with relapsed/refractory ALL

The median age of diagnosis of acute lymphoblastic leukemia (ALL) in the United States is 16 years old, making...

AMELIA: A phase 1 trial of CAR T cells with dual CD19 and CD22 targeting in pediatric and young adult patients with R/R B-ALL

Chimeric antigen receptor (CAR) T cells that target CD19 or CD22 have...

Humoral and cellular responses to tisagenlecleucel

Chimeric antigen receptor (CAR) T-cell therapy has elicited high-response rates in patients with relapsed or refractory (R/R) B-cell malignancies...

Brexucabtagene autoleucel approved by the FDA for use in adult ALL

On October 1, 2021, brexucabtagene autoleucel (brexu-cel) became the first chimeric antigen receptor (CAR) T-cell therapy to be...